Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Myriad Commercially Launches Precise MRD with Select Community Oncologists - Myriad Genetics (NASDAQ:MYGN)

Summary by Benzinga
SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the launch of the Precise MRD™ (molecular residual disease) test with a select number of oncology practices for patients with breast cancer. "The limited release of Precise MRD represents an important milestone in cancer care for patients and the clinicians who guide their care. …

1 Articles

BenzingaBenzinga
Center

Myriad Commercially Launches Precise MRD with Select Community Oncologists - Myriad Genetics (NASDAQ:MYGN)

SALT LAKE CITY, March 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the launch of the Precise MRD™ (molecular residual disease) test with a select number of oncology practices for patients with breast cancer. "The limited release of Precise MRD represents an important milestone in cancer care for patients and the clinicians who guide their care. …

·New York, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Benzinga broke the news in New York, United States on Monday, March 2, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Salt Lake City icon

Salt Lake City

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal